Living Medical Textbook - Hematology - Projects In Knowledge - Insights into Managing Leukemia & MDS Edition Table of Contents

Chapter 2 – Lymphoid Leukemia

Editor-In-Chief
	Jerald P. Radich, MD Professor of Medicine Clinical Research Division University of Washington School of Medicine Member Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Cancer Care Alliance Seattle, Washington
Contributing Editor
	Moshe Talpaz, MD Professor Department of Internal Medicine, Hematology-Oncology University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan
top

Activity Goal
The goal of this CME/CE activity is to review the major chemotherapeutic regimens used to treat chronic lymphoid leukemia and acute lymphoid leukemia and provide rationales for the treatment regimens used for particular patient types and disease phases.

Target Audience
This activity is designed for hematologists, oncologists, radiation oncologists, family practice/primary care physicians, and other clinicians involved in the management, treatment, and care of patients with leukemia.

Learning Objectives

•	Determine the prognostic factors that predict risk of progression in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) to better choose optimal treatments for those patients.
•	Describe the initial treatment regimens for patients with CLL and ALL and the expected response rates to each regimen to optimize patient outcomes.
•	Assess methods used to determine response to therapy in patients with CLL and ALL to optimize treatment regimens that enhance patient outcomes.
•	Describe treatment options for consolidation and maintenance of remission in patients with ALL to prolong patient survival and optimize their quality of life.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.23 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge^® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 2.00 contact hours (0.2 CEUs). The ACPE Universal Program Number assigned to this application activity is 0052-0000-09-095-H01-P.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Jerald P. Radich, MD, is a consultant for Axis Pharmaceuticals and Novartis Pharmaceuticals Corporation; and received research support for Novartis Pharmaceuticals Corporation.

Moshe Talpaz, MD, Moshe Talpaz, MD, has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Exelixis Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Novartis Pharmaceuticals. Dr. Talpaz will be discussing novel treatments for the treatment of chronic myelogenous leukemia, some or all of which may be unlabeled or unapproved for use in the treatment of patients with chronic myelogenous leukemia.

Stephanie G. Phillips, PhD has disclosed no significant relationships.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

1985.02